ArticleDiagnostic molecular pathology : the American journal of surgical pathology, part B2012
Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.
Article in Diagnostic molecular pathology : the American journal of surgical pathology, part B, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study.International journal of molecular sciences · 2022Article
- A multidisciplinary approach to optimize primary prostate cancer biobanking.Urologic oncology · 2022Article
- Article
- Article
- Molecular alterations in prostate cancer and association with MRI features.Prostate cancer and prostatic diseases · 2017Article
- Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO precision oncology · 2017Article
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Nature medicine · 2016Article
- Genomic Characterization and Comparison of Multi-Regional and Pooled Tumor Biopsy Specimens.PloS one · 2016Article
- Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade.Translational pediatrics · 2015Review
- A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.PloS one · 2015Article
- Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue.American journal of translational research · 2015Article
- Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Human pathology · 2014Article
- Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network.The Prostate · 2014Article
- Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank.Biopreservation and biobanking · 2013Article
- Biopsies: next-generation biospecimens for tailoring therapy.Nature reviews. Clinical oncology · 2013Review
- [Personalized urooncology based on molecular uropathology: what is the future?].Der Urologe. Ausg. A · 2013Article
- Biobanking: The Melding of Research with Clinical Care.Current genetic medicine reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Next-generation DNA and RNA sequencing requires intact nucleic acids from high-quality human tissue samples to better elucidate the molecular basis of cancer. We have developed a prostate biobanking protocol to acquire suitable samples for sequencing without compromising the accuracy of clinical diagnosis. To assess the clinical implications of implementing this protocol, we evaluated 105 consecutive radical prostatectomy specimens from November 2008 to February 2009. Alternating levels of prostate samples were submitted to Surgical Pathology as formalin-fixed, paraffin-embedded blocks and to the institutional biobank as frozen blocks. Differences in reported pathologic characteristics between clinical and procured specimens were compared. Clinical staging and grading were not affected by the biobank protocol. Tumor foci on frozen hematoxylin and eosin slides were identified and high-density tumor foci were scored and processed for DNA and RNA extractions for sequencing. Both DNA and RNA were extracted from 22 cases of 44 with high-density tumor foci. Eighty-two percent (18/22) of the samples passed rigorous quality control steps for DNA and RNA sequencing. To date, DNA extracted from 7 cases has undergone whole-genome sequencing, and RNA from 18 cases has been RNA sequenced. This protocol provides prostate tissue for high-throughput biomedical research and confirms the feasibility of actively integrating prostate cancer into The Cancer Genome Atlas Program, a member of the International Cancer Genome Consortium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.